Finance

Cancer vaccine maker files shelf registration statement

Published in Drug Week, December 17th, 2004

CancerVax Corporation (CNVX) announced that it has filed with the U.S. Securities and Exchange Commission a shelf registration statement on Form S-3, which, when declared effective, will permit CancerVax, from time to time, to offer and sell up to $80 million of common stock.

CancerVax plans to use the proceeds from subsequent offerings to continue the clinical development of its lead specific active immunotherapeutic (SAI) product candidate, Canvaxin, to initiate clinical trials of SAI-EGF, its lead SAI product candidate that targets the EGFR signaling pathway, to further the preclinical development of its other product candidates, including its anti-angiogenic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry